Nanoparticles for drug delivery have been designed with all sorts of practical shapes in mind, many of them offering a unique way to hold or release drugs, or to accurately target certain diseases. But researchers at Georgia Tech and other U.S. universities have found that nanoparticles shaped like discs are optimal for gaining entry into human cells.
Getting vaccines to stay in mucosal membranes long enough to trigger an immune response can be tricky. Engineers have now developed nanoparticles to carry vaccines to the mucosal surface in the lungs, protecting them long enough to provoke an immune response.
Diagnostics outfit Nanosphere hauled in $30.2 million in an over-allotted stock sale, padding its war chest as it develops tests using gold nanoparticle chemistry.
Researchers at McGill University in Montreal, Canada, have developed three-dimensional, nanosized cubes made of DNA that can be used to deliver drugs. It marks the first time molecules have been carried within DNA without being attached to the genetic material itself.
Researchers have developed self-powered nanoparticles to carry drugs into tiny cracks in bones, a process that could help treat osteoporosis in its early stages. And the fuel for the nanovehicles' bone-delving ability comes from the bone itself.
Researchers have come up with a way to see what cancer drugs will do in specific patients by mimicking the way human capillaries carry them in the body, making it possible to fine-tune the drugs' targeting mechanisms before conducting pricey, invasive lab tests.
Researchers in Singapore have created silicon "nanocages" to carry protein-based drugs past the body's natural defenses.
Bind Therapeutics, just after filing to go public last week, began dosing its first patient in the second of two Phase II trials of its nanoparticle prostate cancer drug BIND-014.
A needle in the eye is a notoriously unpleasant experience, albeit a necessary one for the treatment of macular degeneration, a condition that can lead to vision loss. And now researchers at Johns Hopkins University have developed a time-release nanoparticle coating to hold drugs in the back of the eye longer, cutting down on the number of injections a patient will need.
Researchers in Massachusetts have designed nanoparticles that carry platinum-based drugs with a one-two-three punch against tumors--the radiotherapy-triggered vehicles attack a tumor's blood vessels, kill the cells that lead to cancer recurrence and, finally, release a chemo drug that specifically targets the cancer.